| Literature DB >> 24769442 |
Kyung Hee Noh1, Seok-Ho Kim2, Jin Hee Kim1, Kwon-Ho Song1, Young-Ho Lee1, Tae Heung Kang3, Hee Dong Han4, Anil K Sood5, Joanne Ng6, Kwanghee Kim7, Chung Hee Sonn6, Vinay Kumar8, Cassian Yee9, Kyung-Mi Lee10, Tae Woo Kim11.
Abstract
Identifying immune escape mechanisms used by tumors may define strategies to sensitize them to immunotherapies to which they are otherwise resistant. In this study, we show that the antiapoptotic gene API5 acts as an immune escape gene in tumors by rendering them resistant to apoptosis triggered by tumor antigen-specific T cells. Its RNAi-mediated silencing in tumor cells expressing high levels of API5 restored antigen-specific immune sensitivity. Conversely, introducing API5 into API5(low) cells conferred immune resistance. Mechanistic investigations revealed that API5 mediated resistance by upregulating FGF2 signaling through a FGFR1/PKCδ/ERK effector pathway that triggered degradation of the proapoptotic molecule BIM. Blockade of FGF2, PKCδ, or ERK phenocopied the effect of API5 silencing in tumor cells expressing high levels of API5 to either murine or human antigen-specific T cells. Our results identify a novel mechanism of immune escape that can be inhibited to potentiate the efficacy of targeted active immunotherapies. ©2014 American Association for Cancer Research.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24769442 PMCID: PMC4394897 DOI: 10.1158/0008-5472.CAN-13-3225
Source DB: PubMed Journal: Cancer Res ISSN: 0008-5472 Impact factor: 12.701